Skip to main content
2025 STS Annual Meeting Main banner
Back

Industry Symposium

Targeting Higher Standards in Resectable NSCLC: The Surgery-Oncology Coalition for Tailoring Care in EGFR & ALK TKI Therapy

Saturday, January 25, 2025
11:55am – 12:55pm PT
Location: 502B

    Industry Speaker(s)

  • Mara B. Antonoff, MD (she/her/hers)

    Associate Professor, Program Director of Education
    UT MD Anderson Cancer Center
    Houston, Texas, United States

    Disclosure(s): BMS, AZ, Merck, Ethicon: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)

  • Karen Reckamp, MD (she/her/hers)

    Director, Division of Medical Oncology
    Cedars Sinai
    Los Angeles, California, United States

    Disclosure(s): AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen, Lilly, Mirati, Novartis, Novocure: Consultant (Terminated, September 11, 2024); Genentech; Blueprint; Daiichi Sankyo; Elevation Oncology; Janssen: research funding to institution (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Disclosure(s):
Mara B. Antonoff, MD: BMS, AZ, Merck, Ethicon: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)
Karen Reckamp, MD: AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen, Lilly, Mirati, Novartis, Novocure: Consultant (Terminated, September 11, 2024); Genentech; Blueprint; Daiichi Sankyo; Elevation Oncology; Janssen: research funding to institution (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)